Scientists said on Monday they had used cloning technology to make embryonic stem cells that carry a diabetic woman’s genes, and turned them into insulin-producing beta cells that may one day cure her disease.
The team reported clearing an important hurdle in the quest to make “personalised stem cells” for use in disease therapy, but a bioethicist said the breakthrough also highlighted the need for better regulation of lab-grown embryos.
“We are now one step closer to being able to treat diabetic patients with their own insulin-producing cells,” said Dieter Egli of the New York Stem Cell Foundation (NYSCF), who led
BioTime Inc, a biotechnology company that develops and markets products in the field of regenerative medicine, and its subsidiaries OrthoCyte Corporation and LifeMap Sciences reported today a means of manufacturing seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells. The paper, scheduled to be published online (ahead of print) at 1600 GMT today in the peer-reviewed journal Regenerative Medicine, characterizes the seven cell types generated using BioTime’s proprietary PureStem(TM) technology. The study compared the novel cells with adult stem cells, known as mesenchymal stem cells (MSCs), and revealed properties of the new cell lines
The master regulator of muscle differentiation, MyoD, functions early in myogenesis to help stem cells proliferate in response to muscle injury, according to researchers at Case Western Reserve University.
The study appears online Jan. 4 in the Journal of Cell Biology.